close

Fundraisings and IPOs

Date: 2011-01-12

Type of information: Fundraising

Company: Vaximm (Switzerland - Germany)

Investors: BB Biotech Ventures (UK) - Merck KGaA (Germany) - Sunstone Capital (Denmark) - Merck Serono Ventures (Germany - Switzerland) - BioMedPartners (Switzerland)

Amount: CHF 7.8 million (€.14 million)

Funding type: financing round

Planned used:

Vaximm plans to use the proceeds of the financing to progress its lead program VXM01 into and through clinical phase I testing. VXM01 is an investigational oral T cell vaccine that is designed to elicit an immune response against vascular growth factor receptor 2 (VEGFR 2), a well characterized target for antiangiogenic intervention. The first human clinical trials of the vaccine are expected to start in 2011.

Others:

Vaximm has announced the closing of a private financing round totalingCHF 7.8 million from new and existing investors. BB Biotech Ventures and Merck KGaA were joined by new investors Sunstone Capital, Merck Serono Ventures and BioMedPartners.

Therapeutic area: Cancer - Oncology

Is general: Yes